Showing results (421-430 of 472) with videos related to

Sort By:
Pageof 48
Frontiers in Veterinary Science|November 10, 2025
Diverse human dimensions affect the management of public and animal health impacts of free-roaming dogs in Australia: a One Health solutionPeter J S Fleming, Benjamin L Allen, Guy Ballard, et al.
Biochemistry|June 30, 2011
Understanding the origins of time-dependent inhibition by polypeptide deformylase inhibitorsRachel Totoritis, Chaya Duraiswami, Amy N Taylor, et al.
Cor Et Vasa|January 1, 1990
Acute effect of intrapulmonary enalaprilat in ten patients with severe pulmonary hypertension due to toxic oil syndromeC Gomez Pajuelo, M A Gomez Sanchez, M Alonso Gutierrez, et al.
Investigative Ophthalmology & Visual Science|October 13, 2011
ADAMTSL4, a secreted glycoprotein widely distributed in the eye, binds fibrillin-1 microfibrils and accelerates microfibril biogenesisLuis A R Gabriel, Lauren W Wang, Hannah Bader, et al.
Revista Clinica Espanola|June 15, 2007
[Relationship between pulse pressure and clinical cardiovascular damage in elderly subjects of EPICARDIAN study]M Fernández-Escribano Hernández, C Suárez Fernández, T Sáez Vaquero, et al.
British Journal of Cancer|May 20, 2004
Negative human papillomavirus testing in normal smears selects a population at low risk for developing high-grade cervical lesionsC Clavel, J Cucherousset, M Lorenzato, et al.
The European Respiratory Journal|April 9, 2002
Interpretation of quality of life scores from the St George's Respiratory QuestionnaireM Ferrer, C Villasante, J Alonso, et al.
Neurotoxicity Research|December 29, 2011
Comparative examination of inner ear in wild type and pituitary adenylate cyclase activating polypeptide (PACAP)-deficient miceA Tamas, K Szabadfi, A Nemeth, et al.
Neurotoxicity Research|July 1, 2011
Mice deficient in pituitary adenylate cyclase activating polypeptide (PACAP) are more susceptible to retinal ischemic injury in vivoK Szabadfi, T Atlasz, P Kiss, et al.
Circulation|June 1, 1990
Quantitation of venous clot lysis with the D-dimer immunoassay during fibrinolytic therapy requires correction for soluble fibrin degradationB Brenner, C W Francis, S Totterman, et al.
Pageof 48